↓ Skip to main content

Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma

Overview of attention for article published in Journal of Hematology & Oncology, October 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Mentioned by

news
1 news outlet
blogs
1 blog
twitter
2 X users
patent
1 patent

Citations

dimensions_citation
561 Dimensions

Readers on

mendeley
279 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma
Published in
Journal of Hematology & Oncology, October 2015
DOI 10.1186/s13045-015-0220-7
Pubmed ID
Authors

Guohua Lou, Xiuli Song, Fan Yang, Shanshan Wu, Jing Wang, Zhi Chen, Yanning Liu

Abstract

Hepatocellular carcinoma (HCC) displays high resistance to conventional chemotherapy. Considering that microRNA-122 (miR-122) performs an essential function to promote chemosensitivity of HCC cells, an effective vehicle-mediated miR-122 delivery may represent a promising strategy for HCC chemotherapy. An increasing interest is focused on the use of exosomes as biological vehicles for microRNAs (miRNA) transfer. Mesenchymal stem cells (MSCs) are known for their capacity to produce large amounts of exosomes. This study aimed to determine whether adipose tissue-derived MSC (AMSC) exosomes can be used for miR-122 delivery. AMSCs were transfected with a miR-122 expression plasmid. At 48 h after transfection, AMSC-derived exosomes (122-Exo) were harvested and added to recipient HCC cells. Expression levels of miR-122 in AMSCs, exosomes, and HCC cells were quantified by real-time PCR. The mRNA and protein levels of miR-122-target genes in recipient HCC cells were quantified by real-time PCR and Western blot, respectively. The effects of 122-Exo on cell viability, apoptosis, and cell cycle of HCC cells were evaluated by MTT and flow cytometry analysis. Xenograft models were used to determine whether 122-Exo can sensitize HCC cells to sorafenib in vivo. Data showed that miR-122-transfected AMSC can effectively package miR-122 into secreted exosomes, which can mediate miR-122 communication between AMSCs and HCC cells, thereby rendering cancer cells sensitive to chemotherapeutic agents through alteration of miR-122-target gene expression in HCC cells. Moreover, intra-tumor injection of 122-Exo significantly increased the antitumor efficacy of sorafenib on HCC in vivo. The findings suggest that the export of miR-122 via AMSC exosomes represents a novel strategy to enhance HCC chemosensitivity.

X Demographics

X Demographics

The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 279 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Spain 1 <1%
China 1 <1%
Denmark 1 <1%
Unknown 275 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 47 17%
Student > Master 40 14%
Researcher 39 14%
Student > Bachelor 31 11%
Student > Postgraduate 13 5%
Other 42 15%
Unknown 67 24%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 87 31%
Medicine and Dentistry 37 13%
Agricultural and Biological Sciences 19 7%
Pharmacology, Toxicology and Pharmaceutical Science 17 6%
Immunology and Microbiology 8 3%
Other 30 11%
Unknown 81 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 20. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 December 2022.
All research outputs
#1,798,777
of 24,932,434 outputs
Outputs from Journal of Hematology & Oncology
#130
of 1,274 outputs
Outputs of similar age
#26,001
of 290,872 outputs
Outputs of similar age from Journal of Hematology & Oncology
#2
of 21 outputs
Altmetric has tracked 24,932,434 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,274 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 13.3. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 290,872 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.